loading
Hutchmed China Limited Adr stock is traded at $13.21, with a volume of 31,439. It is down -1.34% in the last 24 hours and down -12.27% over the past month. HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
See More
Previous Close:
$13.41
Open:
$13.3
24h Volume:
31,439
Relative Volume:
0.35
Market Cap:
$11.51B
Revenue:
$420.26M
Net Income/Loss:
$-41.97M
P/E Ratio:
-52.84
EPS:
-0.25
Net Cash Flow:
$-65.34M
1W Performance:
+0.08%
1M Performance:
-12.27%
6M Performance:
-28.21%
1Y Performance:
-30.91%
1-Day Range:
Value
$13.13
$13.38
1-Week Range:
Value
$13.10
$13.66
52-Week Range:
Value
$11.51
$21.50

Hutchmed China Limited Adr Stock (HCM) Company Profile

Name
Name
Hutchmed China Limited Adr
Name
Phone
-
Name
Address
-
Name
Employee
1,811
Name
Twitter
@hchimed
Name
Next Earnings Date
2025-03-19
Name
Latest SEC Filings
Name
HCM's Discussions on Twitter

Compare HCM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
HCM
Hutchmed China Limited Adr
13.21 2.27B 420.26M -41.97M -65.34M -0.25
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
11.27 49.62B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
165.36 72.86B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
RDHL
Redhill Biopharma Ltd Adr
1.78 4.35M 35.75M 11.57M -26.25M -3.8069
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.57 44.57B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
18.00 19.24B 16.54B -1.64B 749.00M -1.45

Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades

Date Action Analyst Rating Change
May-13-25 Downgrade HSBC Securities Buy → Hold
Nov-24-23 Upgrade Deutsche Bank Hold → Buy
May-04-22 Downgrade Deutsche Bank Buy → Hold
Sep-22-21 Downgrade Goldman Buy → Neutral
Aug-03-21 Initiated Jefferies Buy
Oct-02-20 Initiated Deutsche Bank Buy
Mar-13-20 Initiated Cantor Fitzgerald Overweight
Feb-20-20 Initiated Goldman Buy
Nov-19-19 Initiated CLSA Buy
Oct-23-19 Reiterated BofA/Merrill Buy
Jul-05-19 Initiated Macquarie Outperform
View All

Hutchmed China Limited Adr Stock (HCM) Latest News

pulisher
May 26, 2025

D. E. Shaw & Co. Inc. Trims Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

May 26, 2025
pulisher
May 24, 2025

BNP Paribas Financial Markets Trims Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

May 24, 2025
pulisher
May 20, 2025

Jane Street Group LLC Grows Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

May 20, 2025
pulisher
May 16, 2025

Barclays PLC Purchases 2,255 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

May 16, 2025
pulisher
May 16, 2025

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times

May 16, 2025
pulisher
May 15, 2025

UPDATEInternational companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Globe and Mail

May 15, 2025
pulisher
May 13, 2025

International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Manila Times

May 13, 2025
pulisher
May 12, 2025

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025 - GlobeNewswire Inc.

May 12, 2025
pulisher
May 09, 2025

International companies to host live webcasts at Deutsche - GlobeNewswire

May 09, 2025
pulisher
May 08, 2025

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Globe and Mail

May 08, 2025
pulisher
May 06, 2025

HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial - Barchart.com

May 06, 2025
pulisher
May 05, 2025

Marshall Wace LLP Acquires New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - The AM Reporter

May 05, 2025
pulisher
Apr 29, 2025

CN Reportedly Directs Pharmas, Hospitals to Study Feasibility of Substituting US Imported Products - AASTOCKS.com

Apr 29, 2025
pulisher
Apr 23, 2025

RCSHutchmed China LtdHUTCHMEDData to be Presented at AACR 2025 - TradingView

Apr 23, 2025
pulisher
Apr 21, 2025

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China - Yahoo Finance

Apr 21, 2025
pulisher
Mar 24, 2025

HUTCHMEDOncology portfolio growth expected to continue - Research Tree

Mar 24, 2025
pulisher
Mar 23, 2025

HUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - Defense World

Mar 23, 2025
pulisher
Mar 23, 2025

Richard Li Invited to Attend China Development Forum, Pictured with Li Qiang and Others - AASTOCKS.com

Mar 23, 2025
pulisher
Mar 20, 2025

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees - GlobeNewswire

Mar 20, 2025
pulisher
Mar 19, 2025

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 - GlobeNewswire

Mar 19, 2025
pulisher
Mar 18, 2025

Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 - GlobeNewswire

Mar 18, 2025
pulisher
Mar 09, 2025

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023 - AsiaOne

Mar 09, 2025
pulisher
Feb 20, 2025

HUTCHMED (HCM) Upgraded to Buy: Here's Why - Yahoo Finance

Feb 20, 2025
pulisher
Feb 20, 2025

Wall Street Analysts Believe HUTCHMED (HCM) Could Rally 72.83%: Here's is How to Trade - Yahoo Finance

Feb 20, 2025
pulisher
Feb 19, 2025

CN NMPA Guides Pharmas, Research Institutes to Enlarge R&D of Innovative Drugs, High-Quality Generic Drugs - AASTOCKS.com

Feb 19, 2025
pulisher
Feb 17, 2025

ABC Arbitrage SA Buys New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - MarketBeat

Feb 17, 2025
pulisher
Feb 04, 2025

Sea Limited Sponsored ADR (SE) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance

Feb 04, 2025
pulisher
Jan 28, 2025

Crossmark Global Holdings Inc. Increases Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Jan 28, 2025
pulisher
Jan 16, 2025

CN Healthcare Fund Breaks even w/ Slim Surplus in 2024 - AASTOCKS.com

Jan 16, 2025
pulisher
Jan 13, 2025

HUTCHMED Announces NMPA Full Approval for - GlobeNewswire

Jan 13, 2025
pulisher
Jan 07, 2025

UBS Trims HUTCHMED (00013.HK)TP to $38.7 w/ Rating Buy - AASTOCKS.com

Jan 07, 2025
pulisher
Jan 05, 2025

Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week - Yahoo Finance

Jan 05, 2025
pulisher
Jan 05, 2025

HSBC Global Research Prefers BeiGene/ SINO BIOPHARM/ HYGEIA HEALTH Given Higher Visibility in CN Pharma & Medical Device Subsectors - AASTOCKS.com

Jan 05, 2025
pulisher
Jan 02, 2025

Hutchmed announces progress, hits milestone with lung cancer treatment - ShareCast

Jan 02, 2025
pulisher
Jan 02, 2025

Market news - Research the market

Jan 02, 2025
pulisher
Jan 02, 2025

Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification - OncLive

Jan 02, 2025
pulisher
Jan 01, 2025

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy - The Manila Times

Jan 01, 2025
pulisher
Jan 01, 2025

HUTCHMED Announces NDA Acceptance in China with Priority - GlobeNewswire

Jan 01, 2025
pulisher
Dec 29, 2024

Jane Street Group LLC Raises Stock Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Dec 29, 2024
pulisher
Dec 28, 2024

HUTCHMED (China) Limited (NASDAQ:HCM) Shares Purchased by State Street Corp - Defense World

Dec 28, 2024
pulisher
Dec 12, 2024

HCMHUTCHMED (China) Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan

Dec 12, 2024
pulisher
Dec 12, 2024

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy - The Manila Times

Dec 12, 2024
pulisher
Dec 11, 2024

HUTCHMED Announces Breakthrough Therapy Designation in - GlobeNewswire

Dec 11, 2024
pulisher
Dec 03, 2024

Hutchmed endometrial cancer treatment gets conditional approval in China - ShareCast

Dec 03, 2024
pulisher
Nov 30, 2024

Why Alibaba Group Holding Limited (BABA) Is One of the Best ADR Stocks to Invest in? - Yahoo Finance

Nov 30, 2024
pulisher
Nov 04, 2024

How Trump and Harris plan to address housing affordability - Yahoo Finance

Nov 04, 2024
pulisher
Oct 16, 2024

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® - GlobeNewswire

Oct 16, 2024
pulisher
Oct 15, 2024

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial - Yahoo Finance

Oct 15, 2024

Hutchmed China Limited Adr Stock (HCM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$122.64
price up icon 2.05%
drug_manufacturers_specialty_generic RDY
$14.75
price up icon 2.57%
$8.60
price up icon 3.74%
$316.06
price up icon 2.74%
$17.71
price up icon 4.42%
Cap:     |  Volume (24h):